Spandidos Publications Logo
  • About
    • About Spandidos
    • Aims and Scopes
    • Abstracting and Indexing
    • Editorial Policies
    • Reprints and Permissions
    • Job Opportunities
    • Terms and Conditions
    • Contact
  • Journals
    • All Journals
    • Oncology Letters
      • Oncology Letters
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Oncology
      • International Journal of Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular and Clinical Oncology
      • Molecular and Clinical Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Experimental and Therapeutic Medicine
      • Experimental and Therapeutic Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Molecular Medicine
      • International Journal of Molecular Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Biomedical Reports
      • Biomedical Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Reports
      • Oncology Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular Medicine Reports
      • Molecular Medicine Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • World Academy of Sciences Journal
      • World Academy of Sciences Journal
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Functional Nutrition
      • International Journal of Functional Nutrition
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Epigenetics
      • International Journal of Epigenetics
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Medicine International
      • Medicine International
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
  • Articles
  • Information
    • Information for Authors
    • Information for Reviewers
    • Information for Librarians
    • Information for Advertisers
    • Conferences
  • Language Editing
Spandidos Publications Logo
  • About
    • About Spandidos
    • Aims and Scopes
    • Abstracting and Indexing
    • Editorial Policies
    • Reprints and Permissions
    • Job Opportunities
    • Terms and Conditions
    • Contact
  • Journals
    • All Journals
    • Biomedical Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Experimental and Therapeutic Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Epigenetics
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Functional Nutrition
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Molecular Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Medicine International
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular and Clinical Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular Medicine Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Letters
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • World Academy of Sciences Journal
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
  • Articles
  • Information
    • For Authors
    • For Reviewers
    • For Librarians
    • For Advertisers
    • Conferences
  • Language Editing
Login Register Submit
  • This site uses cookies
  • You can change your cookie settings at any time by following the instructions in our Cookie Policy. To find out more, you may read our Privacy Policy.

    I agree
Search articles by DOI, keyword, author or affiliation
Search
Advanced Search
presentation
Oncology Reports
Join Editorial Board Propose a Special Issue
Print ISSN: 1021-335X Online ISSN: 1791-2431
Journal Cover
February-2022 Volume 47 Issue 2

Full Size Image

Sign up for eToc alerts
Recommend to Library

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

Medicine International

An International Open Access Journal Devoted to General Medicine.

Journal Cover
February-2022 Volume 47 Issue 2

Full Size Image

Sign up for eToc alerts
Recommend to Library

  • Article
  • Citations
    • Cite This Article
    • Download Citation
    • Create Citation Alert
    • Remove Citation Alert
    • Cited By
  • Similar Articles
    • Related Articles (in Spandidos Publications)
    • Similar Articles (Google Scholar)
    • Similar Articles (PubMed)
  • Download PDF
  • Download XML
  • View XML

  • Supplementary Files
    • Supplementary_Data.pdf
Article Open Access

ELOVL2 promotes cancer progression by inhibiting cell apoptosis in renal cell carcinoma

  • Authors:
    • Ken Tanaka
    • Shuya Kandori
    • Shotaro Sakka
    • Satoshi Nitta
    • Kozaburo Tanuma
    • Masanobu Shiga
    • Yoshiyuki Nagumo
    • Hiromitsu Negoro
    • Takahiro Kojima
    • Bryan J. Mathis
    • Toru Shimazui
    • Makoto Watanabe
    • Taka-Aki Sato
    • Takafumi Miyamoto
    • Takashi Matsuzaka
    • Hitoshi Shimano
    • Hiroyuki Nishiyama
  • View Affiliations / Copyright

    Affiliations: Department of Urology, Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki 305‑8577, Japan, International Medical Center, University of Tsukuba Affiliated Hospital, Tsukuba, Ibaraki 305‑8576, Japan, Department of Urology, Ibaraki Prefectural Central Hospital, Kasama, Ibaraki 309‑1793, Japan, Life Science Research Center, Technology Research Laboratory, Shimadzu Corporation, Kyoto 604‑8511, Japan, Department of Endocrinology and Metabolism, Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki 305‑8575, Japan
    Copyright: © Tanaka et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
  • Article Number: 23
    |
    Published online on: November 26, 2021
       https://doi.org/10.3892/or.2021.8234
  • Expand metrics +
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
Cited By (CrossRef): 0 citations Loading Articles...

This article is mentioned in:



Abstract

Renal cell carcinoma (RCC) is an aggressive genitourinary malignancy which has been associated with a poor prognosis, particularly in patients with metastasis, its major subtypes being clear cell RCC (ccRCC), papillary PCC (pRCC) and chromophobe RCC (chRCC). The presence of intracellular lipid droplets (LDs) is considered to be a hallmark of ccRCC. The importance of an altered lipid metabolism in ccRCC has been widely recognized. The elongation of very‑long‑chain fatty acid (ELOVL) catalyzes the elongation of fatty acids (FAs), modulating lipid composition, and is required for normal bodily functions. However, the involvement of elongases in RCC remains unclear. In the present study, the expression of ELOVL2 in ccRCC was examined; in particular, high levels of seven ELOVL isozymes were observed in primary tumors. Of note, elevated ELOVL2 expression levels were observed in ccRCC, as well as in pRCC and chRCC. Furthermore, a higher level of ELOVL2 was significantly associated with the increased incidence of a poor prognosis of patients with ccRCC and pRCC. The CRISPR/Cas9‑mediated knockdown of ELOVL2 resulted in the suppression of the elongation of long‑chain polyunsaturated FAs and increased LD production in renal cancer cells. Moreover, ELOVL2 ablation resulted in the suppression of cellular proliferation via the induction of apoptosis in vitro and the attenuation of tumor growth in vivo. On the whole, the present study provides new insight into the tumor proliferation mechanisms involving lipid metabolism, and suggests that ELOVL2 may be an attractive novel target for RCC therapy.
View Figures

Figure 1

Figure 2

Figure 3

Figure 4

Figure 5

View References

1 

Hsieh JJ, Purdue MP, Signoretti S, Swanton C, Albiges L, Schmidinger M, Heng DY, Larkin J and Ficarra V: Renal cell carcinoma. Nat Rev Dis Primers. 3:170092017. View Article : Google Scholar : PubMed/NCBI

2 

Rini BI, Battle D, Figlin RA, George DJ, Hammers H, Hutson T, Jonasch E, Joseph RW, McDermott DF, Motzer RJ, et al: The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC). J Immunother Cancer. 7:3542019. View Article : Google Scholar : PubMed/NCBI

3 

Walther TC and Farese RV Jr: Lipid droplets and cellular lipid metabolism. Annu Rev Biochem. 81:687–714. 2012. View Article : Google Scholar : PubMed/NCBI

4 

Petan T, Jarc E and Jusović M: Lipid Droplets in Cancer: Guardians of Fat in a Stressful World. Molecules. 23:19412018. View Article : Google Scholar : PubMed/NCBI

5 

Qiu B, Ackerman D, Sanchez DJ, Li B, Ochocki JD, Grazioli A, Bobrovnikova-Marjon E, Diehl JA, Keith B and Simon MC: HIF2α-Dependent Lipid Storage Promotes Endoplasmic Reticulum Homeostasis in Clear-Cell Renal Cell Carcinoma. Cancer Discov. 5:652–667. 2015. View Article : Google Scholar : PubMed/NCBI

6 

Ackerman D, Tumanov S, Qiu B, Michalopoulou E, Spata M, Azzam A, Xie H, Simon MC and Kamphorst JJ: Triglycerides promote lipid homeostasis during hypoxic stress by balancing fatty acid saturation. Cell Rep. 24:2596–2605.e5. 2018. View Article : Google Scholar : PubMed/NCBI

7 

Guillou H, Zadravec D, Martin PG and Jacobsson A: The key roles of elongases and desaturases in mammalian fatty acid metabolism: Insights from transgenic mice. Prog Lipid Res. 49:186–199. 2010. View Article : Google Scholar : PubMed/NCBI

8 

von Roemeling CA, Marlow LA, Wei JJ, Cooper SJ, Caulfield TR, Wu K, Tan WW, Tun HW and Copland JA: Stearoyl-CoA desaturase 1 is a novel molecular therapeutic target for clear cell renal cell carcinoma. Clin Cancer Res. 19:2368–2380. 2013. View Article : Google Scholar : PubMed/NCBI

9 

Lucarelli G, Ferro M, Loizzo D, Bianchi C, Terracciano D, Cantiello F, Bell LN, Battaglia S, Porta C, Gernone A, et al: Integration of Lipidomics and Transcriptomics Reveals Reprogramming of the Lipid Metabolism and Composition in Clear Cell Renal Cell Carcinoma. Metabolites. 10:5092020. View Article : Google Scholar : PubMed/NCBI

10 

Yang H, Zhang X, Liu F, Fan J, Wang B and Dong C: SREBP1-driven lipid desaturation supports clear cell renal cell carcinoma growth through regulation of NF-κB signaling. Biochem Biophys Res Commun. 495:1383–1388. 2018. View Article : Google Scholar : PubMed/NCBI

11 

Pauter AM, Olsson P, Asadi A, Herslöf B, Csikasz RI, Zadravec D and Jacobsson A: Elovl2 ablation demonstrates that systemic DHA is endogenously produced and is essential for lipid homeostasis in mice. J Lipid Res. 55:718–728. 2014. View Article : Google Scholar : PubMed/NCBI

12 

Kobayashi T, Zadravec D and Jacobsson A: ELOVL2 overexpression enhances triacylglycerol synthesis in 3T3-L1 and F442A cells. FEBS Lett. 581:3157–3163. 2007. View Article : Google Scholar : PubMed/NCBI

13 

Lim K, Han C, Xu L, Isse K, Demetris AJ and Wu T: Cyclooxygenase-2-derived prostaglandin E2 activates beta-catenin in human cholangiocarcinoma cells: Evidence for inhibition of these signaling pathways by omega 3 polyunsaturated fatty acids. Cancer Res. 68:553–560. 2008. View Article : Google Scholar : PubMed/NCBI

14 

Yao QH, Zhang XC, Fu T, Gu JZ, Wang L, Wang Y, Lai YB, Wang YQ and Guo Y: ω-3 polyunsaturated fatty acids inhibit the proliferation of the lung adenocarcinoma cell line A549 in vitro. Mol Med Rep. 9:401–406. 2014. View Article : Google Scholar : PubMed/NCBI

15 

Serhan CN, Hong S, Gronert K, Colgan SP, Devchand PR, Mirick G and Moussignac RL: Resolvins: A family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter proinflammation signals. J Exp Med. 196:1025–1037. 2002. View Article : Google Scholar : PubMed/NCBI

16 

Sobin LH, Gospodarowicz MK and Wittekind CH: TNM Classification of Malignant Tumors. (7th edition). Wiley-Blackwell. (Chichester, West Sussex). 2009.

17 

Fuhrman SA, Lasky LC and Limas C: Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol. 6:655–663. 1982. View Article : Google Scholar : PubMed/NCBI

18 

Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI

19 

Kandori S, Kojima T, Matsuoka T, Yoshino T, Sugiyama A, Nakamura E, Shimazui T, Funakoshi Y, Kanaho Y and Nishiyama H: Phospholipase D2 promotes disease progression of renal cell carcinoma through the induction of angiogenin. Cancer Sci. 109:1865–1875. 2018. View Article : Google Scholar : PubMed/NCBI

20 

Grossman RL, Heath AP, Ferretti V, Varmus HE, Lowy DR, Kibbe WA and Staudt LM: Toward a Shared Vision for Cancer Genomic Data. N Engl J Med. 375:1109–1112. 2016. View Article : Google Scholar : PubMed/NCBI

21 

Park SJ, Yoon BH, Kim SK and Kim SY: GENT2: An updated gene expression database for normal and tumor tissues. BMC Med Genomics. 12 (Suppl 5):1012019. View Article : Google Scholar : PubMed/NCBI

22 

Gimple RC, Kidwell RL, Kim LJY, Sun T, Gromovsky AD, Wu Q, Wolf M, Lv D, Bhargava S, Jiang L, et al: Glioma Stem Cell-Specific Superenhancer Promotes Polyunsaturated Fatty-Acid Synthesis to Support EGFR Signaling. Cancer Discov. 9:1248–1267. 2019. View Article : Google Scholar : PubMed/NCBI

23 

Purdy JG, Shenk T and Rabinowitz JD: Fatty acid elongase 7 catalyzes lipidome remodeling essential for human cytomegalovirus replication. Cell Rep. 10:1375–1385. 2015. View Article : Google Scholar : PubMed/NCBI

24 

Cong L, Ran FA, Cox D, Lin S, Barretto R, Habib N, Hsu PD, Wu X, Jiang W, Marraffini LA, et al: Multiplex genome engineering using CRISPR/Cas systems. Science. 339:819–823. 2013. View Article : Google Scholar : PubMed/NCBI

25 

Miyamoto T, Lo PHY, Saichi N, Ueda K, Hirata M, Tanikawa C and Matsuda K: Argininosuccinate synthase 1 is an intrinsic Akt repressor transactivated by p53. Sci Adv. 3:e16032042017. View Article : Google Scholar : PubMed/NCBI

26 

Mishra A, Zennami K, Velarde E, Thorek DLJ, Yegnasubramanian S, DeWeese TL and Lupold SE: Longitudinal measurement of subcutaneous and intratibial human prostate cancer xenograft growth and response to ionizing radiation by plasma Alu and LINE-1 ctDNA: A comparison to standard methods. Prostate. 81:745–753. 2021. View Article : Google Scholar : PubMed/NCBI

27 

Folch J, Lees M and Sloane Stanley GH: A simple method for the isolation and purification of total lipides from animal tissues. J Biol Chem. 226:497–509. 1957. View Article : Google Scholar : PubMed/NCBI

28 

Gregory MK and James MJ: Rainbow trout (Oncorhynchus mykiss) Elovl5 and Elovl2 differ in selectivity for elongation of omega-3 docosapentaenoic acid. Biochim Biophys Acta 1656–60. 20141841.PubMed/NCBI

29 

Gregory MK and James MJ: Functional characterization of the duck and turkey fatty acyl elongase enzymes ELOVL5 and ELOVL2. J Nutr. 144:1234–1239. 2014. View Article : Google Scholar : PubMed/NCBI

30 

Matsuura K, Canfield K, Feng W and Kurokawa M: Metabolic Regulation of Apoptosis in Cancer. Int Rev Cell Mol Biol. 327:43–87. 2016. View Article : Google Scholar : PubMed/NCBI

31 

Kang YP, Yoon JH, Long NP, Koo GB, Noh HJ, Oh SJ, Lee SB, Kim HM, Hong JY, Lee WJ, et al: Spheroid-Induced Epithelial-Mesenchymal Transition Provokes Global Alterations of Breast Cancer Lipidome: A Multi-Layered Omics Analysis. Front Oncol. 9:1452019. View Article : Google Scholar : PubMed/NCBI

32 

Ding Y, Yang J, Ma Y, Yao T, Chen X, Ge S, Wang L and Fan X: MYCN and PRC1 cooperatively repress docosahexaenoic acid synthesis in neuroblastoma via ELOVL2. J Exp Clin Cancer Res. 38:4982019. View Article : Google Scholar : PubMed/NCBI

33 

Matsuyama M, Yoshimura R, Mitsuhashi M, Tsuchida K, Takemoto Y, Kawahito Y, Sano H and Nakatani T: 5-Lipoxygenase inhibitors attenuate growth of human renal cell carcinoma and induce apoptosis through arachidonic acid pathway. Oncol Rep. 14:73–79. 2005.PubMed/NCBI

34 

Matsuyama M and Yoshimura R: Relationship between arachidonic acid pathway and human renal cell carcinoma. OncoTargets Ther. 1:41–48. 2008. View Article : Google Scholar : PubMed/NCBI

35 

Tasaki S, Horiguchi A, Asano T, Ito K, Asano T and Asakura H: Docosahexaenoic acid inhibits the phosphorylation of STAT3 and the growth and invasion of renal cancer cells. Exp Ther Med. 14:1146–1152. 2017. View Article : Google Scholar : PubMed/NCBI

36 

McCabe AJ, Wallace JMW, Gilmore WS, McGlynn H and Strain SJ: Docosahexaenoic acid reduces in vitro invasion of renal cell carcinoma by elevated levels of tissue inhibitor of metalloproteinase-1. J Nutr Biochem. 16:17–22. 2005. View Article : Google Scholar : PubMed/NCBI

37 

Balaban S, Lee LS, Varney B, Aishah A, Gao Q, Shearer RF, Saunders DN, Grewal T and Hoy AJ: Heterogeneity of fatty acid metabolism in breast cancer cells underlies differential sensitivity to palmitate-induced apoptosis. Mol Oncol. 12:1623–1638. 2018. View Article : Google Scholar : PubMed/NCBI

38 

Balaban S, Nassar ZD, Zhang AY, Hosseini-Beheshti E, Centenera MM, Schreuder M, Lin HM, Aishah A, Varney B, Liu-Fu F, et al: Extracellular Fatty Acids Are the Major Contributor to Lipid Synthesis in Prostate Cancer. Mol Cancer Res. 17:949–962. 2019. View Article : Google Scholar : PubMed/NCBI

39 

Bellini L, Campana M, Rouch C, Chacinska M, Bugliani M, Meneyrol K, Hainault I, Lenoir V, Denom J, Véret J, et al: Protective role of the ELOVL2/docosahexaenoic acid axis in glucolipotoxicity-induced apoptosis in rodent beta cells and human islets. Diabetologia. 61:1780–1793. 2018. View Article : Google Scholar : PubMed/NCBI

40 

Masuoka HC, Mott J, Bronk SF, Werneburg NW, Akazawa Y, Kaufmann SH and Gores GJ: Mcl-1 degradation during hepatocyte lipoapoptosis. J Biol Chem. 284:30039–30048. 2009. View Article : Google Scholar : PubMed/NCBI

41 

Shimabukuro M, Wang MY, Zhou YT, Newgard CB and Unger RH: Protection against lipoapoptosis of beta cells through leptin-dependent maintenance of Bcl-2 expression. Proc Natl Acad Sci USA. 95:9558–9561. 1998. View Article : Google Scholar : PubMed/NCBI

42 

Akazawa Y, Cazanave S, Mott JL, Elmi N, Bronk SF, Kohno S, Charlton MR and Gores GJ: Palmitoleate attenuates palmitate-induced Bim and PUMA up-regulation and hepatocyte lipoapoptosis. J Hepatol. 52:586–593. 2010. View Article : Google Scholar : PubMed/NCBI

43 

Cazanave SC, Wang X, Zhou H, Rahmani M, Grant S, Durrant DE, Klaassen CD, Yamamoto M and Sanyal AJ: Degradation of Keap1 activates BH3-only proteins Bim and PUMA during hepatocyte lipoapoptosis. Cell Death Differ. 21:1303–1312. 2014. View Article : Google Scholar : PubMed/NCBI

44 

Hu H, Tian M, Ding C and Yu S: The C/EBP Homologous Protein (CHOP) Transcription Factor Functions in Endoplasmic Reticulum Stress-Induced Apoptosis and Microbial Infection. Front Immunol. 9:30832019. View Article : Google Scholar : PubMed/NCBI

Related Articles

  • Abstract
  • View
  • Download
  • Twitter
Copy and paste a formatted citation
Spandidos Publications style
Tanaka K, Kandori S, Sakka S, Nitta S, Tanuma K, Shiga M, Nagumo Y, Negoro H, Kojima T, Mathis BJ, Mathis BJ, et al: ELOVL2 promotes cancer progression by inhibiting cell apoptosis in renal cell carcinoma. Oncol Rep 47: 23, 2022.
APA
Tanaka, K., Kandori, S., Sakka, S., Nitta, S., Tanuma, K., Shiga, M. ... Nishiyama, H. (2022). ELOVL2 promotes cancer progression by inhibiting cell apoptosis in renal cell carcinoma. Oncology Reports, 47, 23. https://doi.org/10.3892/or.2021.8234
MLA
Tanaka, K., Kandori, S., Sakka, S., Nitta, S., Tanuma, K., Shiga, M., Nagumo, Y., Negoro, H., Kojima, T., Mathis, B. J., Shimazui, T., Watanabe, M., Sato, T., Miyamoto, T., Matsuzaka, T., Shimano, H., Nishiyama, H."ELOVL2 promotes cancer progression by inhibiting cell apoptosis in renal cell carcinoma". Oncology Reports 47.2 (2022): 23.
Chicago
Tanaka, K., Kandori, S., Sakka, S., Nitta, S., Tanuma, K., Shiga, M., Nagumo, Y., Negoro, H., Kojima, T., Mathis, B. J., Shimazui, T., Watanabe, M., Sato, T., Miyamoto, T., Matsuzaka, T., Shimano, H., Nishiyama, H."ELOVL2 promotes cancer progression by inhibiting cell apoptosis in renal cell carcinoma". Oncology Reports 47, no. 2 (2022): 23. https://doi.org/10.3892/or.2021.8234
Copy and paste a formatted citation
x
Spandidos Publications style
Tanaka K, Kandori S, Sakka S, Nitta S, Tanuma K, Shiga M, Nagumo Y, Negoro H, Kojima T, Mathis BJ, Mathis BJ, et al: ELOVL2 promotes cancer progression by inhibiting cell apoptosis in renal cell carcinoma. Oncol Rep 47: 23, 2022.
APA
Tanaka, K., Kandori, S., Sakka, S., Nitta, S., Tanuma, K., Shiga, M. ... Nishiyama, H. (2022). ELOVL2 promotes cancer progression by inhibiting cell apoptosis in renal cell carcinoma. Oncology Reports, 47, 23. https://doi.org/10.3892/or.2021.8234
MLA
Tanaka, K., Kandori, S., Sakka, S., Nitta, S., Tanuma, K., Shiga, M., Nagumo, Y., Negoro, H., Kojima, T., Mathis, B. J., Shimazui, T., Watanabe, M., Sato, T., Miyamoto, T., Matsuzaka, T., Shimano, H., Nishiyama, H."ELOVL2 promotes cancer progression by inhibiting cell apoptosis in renal cell carcinoma". Oncology Reports 47.2 (2022): 23.
Chicago
Tanaka, K., Kandori, S., Sakka, S., Nitta, S., Tanuma, K., Shiga, M., Nagumo, Y., Negoro, H., Kojima, T., Mathis, B. J., Shimazui, T., Watanabe, M., Sato, T., Miyamoto, T., Matsuzaka, T., Shimano, H., Nishiyama, H."ELOVL2 promotes cancer progression by inhibiting cell apoptosis in renal cell carcinoma". Oncology Reports 47, no. 2 (2022): 23. https://doi.org/10.3892/or.2021.8234
Follow us
  • Twitter
  • LinkedIn
  • Facebook
About
  • Spandidos Publications
  • Careers
  • Cookie Policy
  • Privacy Policy
How can we help?
  • Help
  • Live Chat
  • Contact
  • Email to our Support Team